Table 3.
Proportion of patients completing objective disease assessments as part of tight disease monitoring.
| Study, Year, Design | Population (No., UC/CD), Follow-Up |
Interval of Objective Assessment | Proportion of Patients Completing Assessment at Relative Intervals | Outcome Associations |
|---|---|---|---|---|
| Al Khoury et al., 2021, retrospective observational [41] | 428 pts, 338 (79%) CD, 90 (21%) UC |
Three-monthly to 12 months | At 3 months follow-up Clinical: 95.5% CD, 94.3% UC CRP: 70.6% CD, 64% UC Fcal: 25.4% CD, 33.3% UC At 6 months follow-up Clinical: 90.1% CD, 83.8% UC CRP: 54% CD, 52.7% UC Fcal: 24.6% CD, 13.5% UC At 12 months follow-up: Clinical: 95.6% CD, 88.5% UC CRP: 55.2% CD, 51.9% UC Fcal: 29% CD, 19.2% UC |
Clinical remission at 12 months associated with: Combined adherence at 3 months vs. non-adherence in CD, 63.6% vs. 43.3%, p = 0.001. Combined adherence at 3 months vs. non-adherence in UC, 43.9% vs. 20.0%, p = 0.001. |
| Wetwittayakhlang et al., 2022, prospective observational [39] |
104 pts, 82 (79%) CD, 22 (21%) UC, consecutively recruited |
Three-monthly to 12 months | At 3 months follow-up Clinical: 87.7% CD, 90.9% UC CRP: 54.9% CD, 50% UC Fcal: 23.5% CD, 18.2% UC At 6 months follow-up Clinical: 83.8% CD, 90% UC CRP: 46.3% CD, 50% UC Fcal: 31.3% CD, 25% UC At 12 months follow-up: Clinical: 81.3% CD, 76.5% UC CRP: 37.3% CD, 29.4% UC Fcal: 22.7% CD, 17.6% UC Endoscopy in first 6 months: 21.5% CD, 40.9% UC Endoscopy in second 6 months: 26.3% CD, 34.6% UC |
Clinical remission at 12 months associated with: Early combined adherence vs. non-adherence in CD (70.2% vs. 29.8%, p = 0.007). Earlier dose optimisation of adalimumab associated with: Early combined adherence at 3 and 6 months in CD and UC (log-rank < 0.001). |
| Click et al., 2022, data from prospective longitudinal cohort [40] | 525 pts, 375 (71.4%) CD, 150 (28.6%) UC |
Within 12 weeks prior to dose escalation or cessation of biologic therapy | Prior to escalation of therapy (n = 292) ≥1 measure: 67.9% CD, 66.32% UC ≥2 measures: 33.5% CD, 42.9% UC CRP: 39.1% CD, 54.5% UC Fcal: 5.6% CD, 13% UC Endoscopy: 26.5% CD, 23.4% UC Prior to discontinuation of therapy (n = 233) ≥1 measure: 79.4% CD, 79.5% UC ≥2 measures: 44.4% CD, 38.4% UC CRP: 46.3% CD, 35.6% UC Fcal: 6.9% CD, 8.2% UC Endoscopy: 33.1% CD, 39.7% UC |
N/A |
CD, Crohn’s disease; CRP, C-reactive protein; Fcal, faecal calprotectin; No., number; Pts, patients; UC, ulcerative colitis.